UBS Group Cuts Owens & Minor (NYSE:OMI) Price Target to $13.00

Owens & Minor (NYSE:OMI) had its price objective decreased by investment analysts at UBS Group from $25.00 to $13.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 74.61% from the stock’s previous close.

OMI has been the subject of several other research reports. Robert W. Baird dropped their target price on shares of Owens & Minor from $15.00 to $14.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Citigroup lowered their price objective on shares of Owens & Minor from $21.00 to $18.50 and set a “buy” rating for the company in a research report on Tuesday, November 5th. Finally, Barclays lowered their price objective on shares of Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 5th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Owens & Minor presently has an average rating of “Hold” and a consensus price target of $16.79.

Owens & Minor Stock Performance

OMI stock opened at $7.45 on Thursday. The company has a 50 day moving average price of $12.80 and a 200 day moving average price of $13.85. The stock has a market capitalization of $574.08 million, a PE ratio of -11.45, a price-to-earnings-growth ratio of 0.25 and a beta of 0.48. Owens & Minor has a fifty-two week low of $7.41 and a fifty-two week high of $28.35. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.09 and a quick ratio of 0.45.

Insider Buying and Selling

In related news, CFO Jonathan A. Leon sold 5,282 shares of the company’s stock in a transaction on Thursday, November 21st. The shares were sold at an average price of $11.82, for a total value of $62,433.24. Following the completion of the transaction, the chief financial officer now directly owns 130,822 shares of the company’s stock, valued at approximately $1,546,316.04. This represents a 3.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 3.59% of the company’s stock.

Hedge Funds Weigh In On Owens & Minor

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Inspire Advisors LLC boosted its stake in shares of Owens & Minor by 11.2% during the 4th quarter. Inspire Advisors LLC now owns 15,350 shares of the company’s stock worth $201,000 after buying an additional 1,548 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Owens & Minor by 57.4% during the 4th quarter. Blue Trust Inc. now owns 4,387 shares of the company’s stock worth $57,000 after buying an additional 1,600 shares during the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Owens & Minor by 4.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,366 shares of the company’s stock worth $491,000 after buying an additional 1,709 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Owens & Minor by 758.3% during the 4th quarter. Sterling Capital Management LLC now owns 2,060 shares of the company’s stock worth $27,000 after buying an additional 1,820 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Owens & Minor by 0.9% during the 4th quarter. Legal & General Group Plc now owns 212,061 shares of the company’s stock worth $2,772,000 after buying an additional 1,991 shares during the last quarter. 98.04% of the stock is owned by institutional investors and hedge funds.

About Owens & Minor

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.